ACADIA Pharmaceuticals Inc.
General ticker "ACAD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.4B (TTM average)
ACADIA Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 58.2%.
Estimated limits based on current volatility of 3.5%: low 21.94$, high 23.53$
Factors to consider:
- Total employees count: 654 (+9.4%) as of 2024
- Top business risk factors: Commercialization challenges, Leadership changes, Economic downturns and volatility, Supply chain disruptions, Acquisition/divestiture risks
- Price in estimated range
- Earnings for 12 months up through Q4 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [13.96$, 25.00$]
- 2025-12-31 to 2026-12-31 estimated range: [14.98$, 26.49$]
Financial Metrics affecting the ACAD estimates:
- Positive: with PPE of 25.6 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 24.10 > 18.38
- Positive: Return on assets ratio (scaled to [-100,100]) of 16.01 > 6.11
- Positive: 0.01 < Operating cash flow per share per price, % of 5.55
- Negative: negative Industry operating income (median)
- Negative: 42.68 < Shareholder equity ratio, % of 61.70 <= 64.29
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Investing cash flow per share per price, % of -1.07 <= -0.63
- Negative: Industry earnings per price (median), % of -15.81 <= 0
Short-term ACAD quotes
Long-term ACAD plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $517.24MM | $726.44MM | $957.80MM |
| Operating Expenses | $740.83MM | $799.82MM | $727.00MM |
| Operating Income | $-223.60MM | $-73.38MM | $230.79MM |
| Non-Operating Income | $10.15MM | $22.34MM | $27.28MM |
| R&D Expense | $361.57MM | $351.62MM | $303.25MM |
| Income(Loss) | $-213.44MM | $-51.04MM | $258.07MM |
| Taxes | $2.53MM | $10.25MM | $31.62MM |
| Profit(Loss)* | $-215.97MM | $-61.29MM | $226.45MM |
| Stockholders Equity | $400.41MM | $431.75MM | $732.79MM |
| Inventory | $6.64MM | $35.82MM | $21.95MM |
| Assets | $587.81MM | $748.96MM | $1,187.76MM |
| Operating Cash Flow | $-114.03MM | $16.70MM | $157.72MM |
| Capital expenditure | $0.00MM | $40.05MM | $0.52MM |
| Investing Cash Flow | $73.24MM | $32.00MM | $-30.54MM |
| Financing Cash Flow | $8.20MM | $25.13MM | $6.84MM |
| Earnings Per Share** | $-1.34 | $-0.37 | $1.37 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.